keyword
https://read.qxmd.com/read/38513086/optimization-of-potent-ligands-for-the-e3-ligase-dcaf15-and-evaluation-of-their-use-in-heterobifunctional-degraders
#1
JOURNAL ARTICLE
Simon C C Lucas, Afshan Ahmed, S Neha Ashraf, Argyrides Argyrou, Matthias R Bauer, Gian Marco De Donatis, Sylvain Demanze, Frederik Eisele, Lucia Fusani, Andreas Hock, Ganesh Kadamur, Shuyou Li, Abigail Macmillan-Jones, Iacovos N Michaelides, Christopher Phillips, Marie Rehnström, Magdalena Richter, Monica C Rodrigo-Brenni, Fiona Shilliday, Peng Wang, R Ian Storer
Unlocking novel E3 ligases for use in heterobifunctional PROTAC degraders is of high importance to the pharmaceutical industry. Over-reliance on the current suite of ligands used to recruit E3 ligases could limit the potential of their application. To address this, potent ligands for DCAF15 were optimized using cryo-EM supported, structure-based design to improve on micromolar starting points. A potent binder, compound 24 , was identified and subsequently conjugated into PROTACs against multiple targets. Following attempts on degrading a number of proteins using DCAF15 recruiting PROTACs, only degradation of BRD4 was observed...
March 21, 2024: Journal of Medicinal Chemistry
https://read.qxmd.com/read/37858464/pharmacological-depletion-of-rna-splicing-factor-rbm39-by-indisulam-synergizes-with-parp-inhibitors-in-high-grade-serous-ovarian-carcinoma
#2
JOURNAL ARTICLE
Yuewei Xu, Sarah Spear, Yurui Ma, Marc P Lorentzen, Michael Gruet, Flora McKinney, Yitao Xu, Chiharu Wickremesinghe, Madelen R Shepherd, Iain McNeish, Hector C Keun, Anke Nijhuis
Ovarian high-grade serous carcinoma (HGSC) is the most common subtype of ovarian cancer with limited therapeutic options and a poor prognosis. In recent years, poly-ADP ribose polymerase (PARP) inhibitors have demonstrated significant clinical benefits, especially in patients with BRCA1/2 mutations. However, acquired drug resistance and relapse is a major challenge. Indisulam (E7070) has been identified as a molecular glue that brings together splicing factor RBM39 and DCAF15 E3 ubiquitin ligase resulting in polyubiquitination, degradation, and subsequent RNA splicing defects...
October 18, 2023: Cell Reports
https://read.qxmd.com/read/37666821/molecular-basis-of-rna-binding-and-autoregulation-by-the-cancer-associated-splicing-factor-rbm39
#3
JOURNAL ARTICLE
Sébastien Campagne, Daniel Jutzi, Florian Malard, Maja Matoga, Ksenija Romane, Miki Feldmuller, Martino Colombo, Marc-David Ruepp, Frédéric H-T Allain
Pharmacologic depletion of RNA-binding motif 39 (RBM39) using aryl sulfonamides represents a promising anti-cancer therapy but requires high levels of the adaptor protein DCAF15. Consequently, novel approaches to deplete RBM39 in an DCAF15-independent manner are required. Here, we uncover that RBM39 autoregulates via the inclusion of a poison exon into its own pre-mRNA and identify the cis-acting elements that govern this regulation. We also determine the NMR solution structures of RBM39's tandem RNA recognition motifs (RRM1 and RRM2) bound to their respective RNA targets, revealing how RRM1 recognises RNA stem loops whereas RRM2 binds specifically to single-stranded N(G/U)NUUUG...
September 4, 2023: Nature Communications
https://read.qxmd.com/read/37255411/overlaid-transcriptional-and-proteome-analyses-identify-mitotic-kinesins-as-important-targets-of-arylsulfonamide-mediated-rbm39-degradation
#4
JOURNAL ARTICLE
Seemon Coomar, Pedro Mota, Alexander Penson, Jürg Schwaller, Omar Abdel-Wahab, Dennis Gillingham
UNLABELLED: Certain arylsulfonamides (ArSulf) induce an interaction between the E3 ligase substrate adaptor DCAF15 and the critical splicing factor RBM39, ultimately causing its degradation. However, degradation of a splicing factor introduces complex pleiotropic effects that are difficult to untangle, since, aside from direct protein degradation, downstream transcriptional effects also influence the proteome. By overlaying transcriptional data and proteome datasets, we distinguish transcriptional from direct degradation effects, pinpointing those proteins most impacted by splicing changes...
May 31, 2023: Molecular Cancer Research: MCR
https://read.qxmd.com/read/37171980/overlaid-transcriptome-and-proteome-analyses-identify-mitotic-kinesins-as-important-targets-of-arylsulfonamide-mediated-rbm39-degradation
#5
JOURNAL ARTICLE
Seemon Coomar, Pedro Mota, Alexander Penson, Juerg Schwaller, Omar Abdel-Wahab, Dennis Gillingham
Certain arylsulfonamides (ArSulfs) induce an interaction between the E3 ligase substrate adaptor DCAF15 and the critical splicing factor RBM39, ultimately causing its degradation. However, degradation of a splicing factor introduces complex pleiotropic effects that are difficult to untangle, since, aside from direct protein degradation, downstream transcriptional effects also influence the proteome. By overlaying transcriptional data and proteome datasets, we distinguish transcriptional from direct degradation effects, pinpointing those proteins most impacted by splicing changes...
May 12, 2023: Molecular Cancer Research: MCR
https://read.qxmd.com/read/36805336/the-aryl-sulfonamide-indisulam-inhibits-gastric-cancer-cell-migration-by-promoting-the-ubiquitination-and-degradation-of-the-transcription-factor-zeb1
#6
JOURNAL ARTICLE
Jiaqi Lu, Dan Li, Honglv Jiang, Yue Li, Chengpaio Lu, Tao Chen, Yuhong Wang, Xiaohui Wang, Wenzhao Sun, Zhongjian Pu, Chunhua Qiao, Jingjing Ma, Guoqiang Xu
Gastric cancer is one of the cancers with high morbidity and mortality worldwide. The aryl sulfonamide indisulam inhibits the proliferation of several types of cancer cells through its function as a molecular glue to promote the ubiquitination and degradation of RNA-binding motif protein 39 (RBM39). However, it is unknown whether and how indisulam regulates the migration of cancer cells. In this work, using label-free quantitative proteomics, we discover that indisulam significantly attenuates N-cadherin, a marker for epithelial to mesenchymal transition (EMT) and migration of cancer cells...
February 15, 2023: Journal of Biological Chemistry
https://read.qxmd.com/read/36656921/crispr-screen-reveals-brd2-4-molecular-glue-like-degrader-via-recruitment-of-dcaf16
#7
JOURNAL ARTICLE
Andrea G Shergalis, Violeta L Marin, David Y Rhee, Sameera Senaweera, Rebecca L McCloud, Judith A Ronau, Charles W Hutchins, Shaun McLoughlin, Kevin R Woller, Scott E Warder, Anil Vasudevan, Justin M Reitsma
Molecular glues (MGs) are monovalent small molecules that induce an interaction between proteins (native or non-native partners) by altering the protein-protein interaction (PPI) interface toward a higher-affinity state. Enhancing the PPI between a protein and E3 ubiquitin ligase can lead to degradation of the partnering protein. Over the past decade, retrospective studies of clinical drugs identified that immunomodulatory drugs (e.g., thalidomide and analogues) and indisulam exhibit a molecular glue effect by driving the interaction between non-native substrates to CRBN and DCAF15 ligases, respectively...
January 19, 2023: ACS Chemical Biology
https://read.qxmd.com/read/36602777/e3-specific-degrader-discovery-by-dynamic-tracing-of-substrate-receptor-abundance
#8
JOURNAL ARTICLE
Alexander Hanzl, Eleonora Barone, Sophie Bauer, Hong Yue, Radosław P Nowak, Elisa Hahn, Eugenia V Pankevich, Anna Koren, Stefan Kubicek, Eric S Fischer, Georg E Winter
Targeted protein degradation (TPD) is a new pharmacology based on small-molecule degraders that induce proximity between a protein of interest (POI) and an E3 ubiquitin ligase. Of the approximately 600 E3s encoded in the human genome, only around 2% can be co-opted with degraders. This underrepresentation is caused by a paucity of discovery approaches to identify degraders for defined E3s. This hampers a rational expansion of the druggable proteome and stymies critical advancements in the field, such as tissue- and cell-specific degradation...
January 5, 2023: Journal of the American Chemical Society
https://read.qxmd.com/read/36479111/short-term-oral-pre-exposure-prophylaxis-against-hiv-1-modulates-the-transcriptome-of-foreskin-tissue-in-young-men-in-africa
#9
JOURNAL ARTICLE
Stefan Petkov, Carolina Herrera, Laura Else, Limakatso Lebina, Daniel Opoka, Thabiso B Seiphetlo, Azure-Dee Ap Pillay, Susan Mugaba, Patricia Namubiru, Geoffrey Odoch, Andrew S Ssemata, Jennifer Serwanga, Pontiano Kaleebu, Emily L Webb, Saye Khoo, Neil Martinson, Clive M Gray, Julie Fox, Francesca Chiodi
Whilst short-term oral pre-exposure prophylaxis (PrEP) with antiretroviral drugs in men who have sex with men has shown protection against HIV-1 infection, the impact of this regimen on the in vivo foreskin transcriptome is unknown. We collected foreskin tissue after voluntary medical male circumcision from 144 young men (72 from Uganda and 72 from South Africa) randomized to one to two doses of either oral tenofovir (TFV) disoproxil fumarate (FTC-TDF) or tenofovir alafenamide (FTC-TAF) or no drug (untreated controls)...
2022: Frontiers in Immunology
https://read.qxmd.com/read/35534224/genetic-and-compound-screens-uncover-factors-modulating-cancer-cell-response-to-indisulam
#10
JOURNAL ARTICLE
Ziva Pogacar, Kelvin Groot, Fleur Jochems, Matheus Dos Santos Dias, Antonio Mulero-Sánchez, Ben Morris, Mieke Roosen, Leyma Wardak, Giulia De Conti, Arno Velds, Cor Lieftink, Bram Thijssen, Roderick L Beijersbergen, René Bernards, Rodrigo Leite de Oliveira
Discovering biomarkers of drug response and finding powerful drug combinations can support the reuse of previously abandoned cancer drugs in the clinic. Indisulam is an abandoned drug that acts as a molecular glue, inducing degradation of splicing factor RBM39 through interaction with CRL4DCAF15 Here, we performed genetic and compound screens to uncover factors mediating indisulam sensitivity and resistance. First, a dropout CRISPR screen identified SRPK1 loss as a synthetic lethal interaction with indisulam that can be exploited therapeutically by the SRPK1 inhibitor SPHINX31...
September 2022: Life Science Alliance
https://read.qxmd.com/read/35505873/profiling-the-landscape-of-drug-resistance-mutations-in-neosubstrates-to-molecular-glue-degraders
#11
JOURNAL ARTICLE
Pallavi M Gosavi, Kevin C Ngan, Megan J R Yeo, Cindy Su, Jiaming Li, Nicholas Z Lue, Samuel M Hoenig, Brian B Liau
Targeted protein degradation (TPD) holds immense promise for drug discovery, but mechanisms of acquired resistance to degraders remain to be fully identified. Here, we used clustered regularly interspaced short palindromic repeats (CRISPR)-suppressor scanning to identify mechanistic classes of drug resistance mutations to molecular glue degraders in GSPT1 and RBM39, neosubstrates targeted by E3 ligase substrate receptors cereblon and DCAF15, respectively. While many mutations directly alter the ternary complex heterodimerization surface, distal resistance sites were also identified...
April 27, 2022: ACS Central Science
https://read.qxmd.com/read/35013300/a-proximity-biotinylation-based-approach-to-identify-protein-e3-ligase-interactions-induced-by-protacs-and-molecular-glues
#12
JOURNAL ARTICLE
Satoshi Yamanaka, Yuto Horiuchi, Saya Matsuoka, Kohki Kido, Kohei Nishino, Mayaka Maeno, Norio Shibata, Hidetaka Kosako, Tatsuya Sawasaki
Proteolysis-targeting chimaeras (PROTACs) as well as molecular glues such as immunomodulatory drugs (IMiDs) and indisulam are drugs that induce interactions between substrate proteins and an E3 ubiquitin ligases for targeted protein degradation. Here, we develop a workflow based on proximity-dependent biotinylation by AirID to identify drug-induced neo-substrates of the E3 ligase cereblon (CRBN). Using AirID-CRBN, we detect IMiD-dependent biotinylation of CRBN neo-substrates in vitro and identify biotinylated peptides of well-known neo-substrates by mass spectrometry with high specificity and selectivity...
January 10, 2022: Nature Communications
https://read.qxmd.com/read/34420308/proximity-labeling-quantitative-proteomics-and-biochemical-studies-revealed-the-molecular-mechanism-for-the-inhibitory-effect-of-indisulam-on-the-proliferation-of-gastric-cancer-cells
#13
JOURNAL ARTICLE
Jiaqi Lu, Honglv Jiang, Dan Li, Tao Chen, Yuhong Wang, Zhongjian Pu, Guoqiang Xu
Indisulam exhibits antitumor activity against several cancer cells. Although the DCAF15-indisulam-RBM39 axis has been well documented in the inhibition of cancer cell growth, it is unknown whether RBM39 degradation alone is the mechanism of action of indisulam. Here, we verified the inhibitory effect of indisulam on the proliferation of gastric cancer cells and its dependence on DCAF15. Proximity-dependent biotin labeling with TurboID and quantitative proteomics revealed that indisulam indeed promoted the interaction between DCAF15 and RBM39...
September 3, 2021: Journal of Proteome Research
https://read.qxmd.com/read/34411892/developments-of-crbn-based-protacs-as-potential-therapeutic-agents
#14
REVIEW
Chao Wang, Yujing Zhang, Yudong Wu, Dongming Xing
Protease-targeted chimeras (PROTACs) are a new technology that is receiving much attention in the treatment of diseases. The mechanism is to inhibit protein function by hijacking the ubiquitin E3 ligase for protein degradation. Heterogeneous bifunctional PROTACs contain a ligand for recruiting E3 ligase, a linker, and another ligand to bind to the target protein for degradation. A variety of small-molecule PROTACs (CRBN, VHL, IAPs, MDM2, DCAF15, DCAF16, and RNF114-based PROTACs) have been identified so far...
December 5, 2021: European Journal of Medicinal Chemistry
https://read.qxmd.com/read/34257283/targeting-kras4a-splicing-through-the-rbm39-dcaf15-pathway-inhibits-cancer-stem-cells
#15
JOURNAL ARTICLE
Wei-Ching Chen, Minh D To, Peter M K Westcott, Reyno Delrosario, Il-Jin Kim, Mark Philips, Quan Tran, Saumya R Bollam, Hani Goodarzi, Nora Bayani, Olga Mirzoeva, Allan Balmain
The commonly mutated human KRAS oncogene encodes two distinct KRAS4A and KRAS4B proteins generated by differential splicing. We demonstrate here that coordinated regulation of both isoforms through control of splicing is essential for development of Kras mutant tumors. The minor KRAS4A isoform is enriched in cancer stem-like cells, where it responds to hypoxia, while the major KRAS4B is induced by ER stress. KRAS4A splicing is controlled by the DCAF15/RBM39 pathway, and deletion of KRAS4A or pharmacological inhibition of RBM39 using Indisulam leads to inhibition of cancer stem cells...
July 13, 2021: Nature Communications
https://read.qxmd.com/read/33833131/tumor-suppressor-dcaf15-inhibits-epithelial-mesenchymal-transition-by-targeting-zeb1-for-proteasomal-degradation-in-hepatocellular-carcinoma
#16
JOURNAL ARTICLE
Xiao Dong, Yang Han, Encheng Zhang, Yuqi Wang, Pingzhao Zhang, Chenji Wang, Lin Zhong, Qi Li
Epithelial-mesenchymal transition (EMT) is an evolutionarily conserved developmental program that has been implicated in tumorigenesis and confers metastatic properties upon cancer cells. ZEB1 is a master transcription factor that activates the EMT process in various cancers. ZEB1 is reportedly degraded through the ubiquitin proteasome pathway, but the underlying molecular mechanism of this process remains largely unknown in hepatocellular carcinoma (HCC). Here, we identified ZEB1 as a substrate of the CRL4-DCAF15 (DDB1 and CUL4 associated factor 15) E3 ubiquitin ligase complex...
April 4, 2021: Aging
https://read.qxmd.com/read/33238031/rna-binding-motif-protein-39-rbm39-an-emerging-cancer-target
#17
REVIEW
Yuewei Xu, Anke Nijhuis, Hector C Keun
RNA-binding motif protein 39 (RBM39) is an RNA-binding protein involved in transcriptional co-regulation and alternative RNA splicing. Recent studies have revealed that RBM39 is the unexpected target of aryl sulphonamides, which act as molecular glues between RBM39 and the DCAF15-associated E3 ubiquitin ligase complex leading to selective degradation of the target. Loss of RBM39 leads to aberrant splicing events and differential gene expression, thereby inhibiting cell cycle progression and causing tumour regression in a number of preclinical models...
June 2022: British Journal of Pharmacology
https://read.qxmd.com/read/33168788/aryl-sulfonamides-induce-degradation-of-aryl-hydrocarbon-receptor-nuclear-translocator-through-crl4-dcaf15-e3-ligase
#18
JOURNAL ARTICLE
Sung Ah Kim, Seung-Hyun Jo, Jin Hwa Cho, Min Yeong Yu, Ho-Chul Shin, Jung-Ae Kim, Sung Goo Park, Byoung Chul Park, Sunhong Kim, Jeong-Hoon Kim
Aryl hydrocarbon receptor nuclear translocator (ARNT) plays an essential role in maintaining cellular homeostasis in response to environmental stress. Under conditions of hypoxia or xenobiotic exposure, ARNT regulates the subset of genes involved in adaptive responses, by forming heterodimers with hypoxia-inducible transcription factors (HIF1α and HIF2α) or aryl hydrocarbon receptor (AhR). Here, we have shown that ARNT interacts with DDB1 and CUL4-associated factor 15 (DCAF15), and the aryl sulfonamides, indisulam and E7820, induce its proteasomal degradation through Cullin-RING finger ligase 4 containing DCAF15 (CRL4DCAF15 ) E3 ligase...
November 10, 2020: Molecules and Cells
https://read.qxmd.com/read/32200025/targeting-the-e3-ubiquitin-ligases-dcaf15-and-cereblon-for-cancer-therapy
#19
REVIEW
Khai M Nguyen, Luca Busino
Small molecule-mediated inhibition of protein function is the rational behind therapeutic efficacy of the majority clinically used drugs. In order for a drug to achieve pharmacologically relevant inhibition, efficient target engagement at high selectivity and specificity is necessary to obtain the desired therapeutic effect minimizing offtarget outcomes. Majority of small molecules approaches developed so far have failed in their attempt to reach clinical efficacy because of low selectivity and low specificity in achieving close to 100 % target inhibition...
December 2020: Seminars in Cancer Biology
https://read.qxmd.com/read/31942047/author-correction-structural-basis-of-indisulam-mediated-rbm39-recruitment-to-dcaf15-e3-ligase-complex
#20
Dirksen E Bussiere, Lili Xie, Honnappa Srinivas, Wei Shu, Ashley Burke, Celine Be, Junping Zhao, Adarsh Godbole, Dan King, Rajeshri G Karki, Viktor Hornak, Fangmin Xu, Jennifer Cobb, Nathalie Carte, Andreas O Frank, Alexandra Frommlet, Patrick Graff, Mark Knapp, Aleem Fazal, Barun Okram, Songchun Jiang, Pierre-Yves Michellys, Rohan Beckwith, Hans Voshol, Christian Wiesmann, Jonathan M Solomon, Joshiawa Paulk
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
March 2020: Nature Chemical Biology
keyword
keyword
166289
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.